Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus
Anne Hiukka, MD*,
Jukka Westerbacka, MD, PhD ,
Eeva S. Leinonen, MD, PhD*,
Hiroshi Watanabe, MD, PhD*,
Olov Wiklund, MD, PhD ,
Lillemor Mattson Hulten, PhD ,
Jukka T. Salonen, DMedSc ,||,
Tomi-Pekka Tuomainen, MD, PhD ,
Hannele Yki-Järvinen, MD, PhD ,
Anthony C. Keech, MD, PhD¶ and
Marja-Riitta Taskinen, MD, PhD*,*
* Department of Medicine, University of Helsinki, Helsinki University Central Hospital and Biomedicum, Helsinki, Finland
Department of Diabetes, University of Helsinki, Helsinki University Central Hospital and Biomedicum, Helsinki, Finland
Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Göteborg, Sweden
Research Institute of Public Health, University of Kuopio, Kuopio, Finland
|| Oy Jurilab Ltd., Kuopio, Finland
¶ NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Results of the Maximal and Mean IMT in Fenofibrate and Placebo Groups During the Study
Black circles and solid lines = fenofibrate group; open circles and dotted lines = placebo group. Data are mean ± SD. IMT = intima-media thickness.
|
|
|